There are also concerns about whether the frequent baseline use of immunosuppressants such as corticosteroids at the beginning of PD-1/PD-L1 inhibitors in AID patients may reduce efficacy in these patients; whether the status and types of autoimmune diseases will alter the risk of adverse events; and whether patients with underlying autoimmune diseases may benefit more from immunotherapy. This evidence concerns the gene PDCD1 and autoimmune disease.